세계의 마우스 모델 시장(-2030년) : 모델 유형별(근교계, 비근교계, 하이브리드), 서비스별(번식, 재생), 용도별(맞춤형 의료), 기술별(마이크로인젝션, CRISPR/Cas9), 치료 분야별(종양, 신경), 최종사용자별(CRO)

The mice model market is projected to reach USD 2.74 billion by 2030 from USD 1.70 billion in 2025, at a CAGR of 10.0% during the forecast period.

The growth of this market is driven by several factors, such as rising adoption of mice models in preclinical studies due to genetic & physiological versatility; the increasing demand for mouse clinical trials (MCTs); the rising demand for personalized medicine in oncology; and advancements in genetic engineering. Utilization of CRISPR in biomedical research and the increasing demand for disease-specific models are also expected to contribute to market growth during the forecast period.

By model type, the inbred mice segment accounted for the largest share of the market in 2024.

The market is segmented by model type into inbred mice, genetically engineered mice, hybrid/congenic mice, and outbred mice. In 2024, the inbred mice segment accounted for the largest share of the mice model market. The large share of the inbred mice segment is attributed to the ability of inbred strains to provide genetic uniformity for preclinical studies, standardized breeding protocols that enable scalable production, and supply chains that support continuous availability. Regulatory frameworks at national and international levels recognize inbred strains as reference models for efficacy and safety assessment, and centralized breeding facilities implement quality control measures to maintain strain integrity. Adoption of inbred mice spans pharmaceutical and biotechnology companies and academic and government research institutions, where controlled genetic backgrounds reduce experimental variability.

By application, the drug discovery & development segment accounted for the largest share of the market in 2024.

The mice model market is segmented into drug discovery & development, research applications, and personalized medicine. In 2024, the drug discovery & development segment accounted for the largest share of the market. Mouse models are deployed in target validation assays to confirm the relevance of molecular targets, in lead optimization studies to compare pharmacodynamic profiles, and in efficacy evaluations to measure treatment responses under controlled conditions. Safety pharmacology protocols-cardiovascular, respiratory, and central nervous system endpoints-rely on telemetry recordings and behavioral assays conducted in mice. At the same time, reproductive and developmental toxicity assessments use timed-pregnancy protocols to determine embryonic viability and teratogenic risk. Histopathological examinations and clinical chemistry analyses of tissue samples support regulatory submissions, and omics profiling (transcriptomics, proteomics, metabolomics) informs dose selection and mechanism-of-action studies. Service providers integrate these applications into end-to-end workflows for end users. Combined, these integrated applications ensure the dominance of drug discovery & development applications in the mice model market.

By region, North America accounted for the largest share of the mice model market in 2024.

In 2024, North America accounted for the largest share of the mice model market due to the concentration of major contract research organizations and breeding suppliers, government and private funding mechanisms, and a regulatory environment emphasizing standardized preclinical practices. The key market players, such as Charles River Laboratories (US), The Jackson Laboratory (US), and Inotiv (US), have their presence in the region, thus ensuring regional supply and technical support. Public funding agencies such as the National Institutes of Health (NIH) allocate substantial budgets to basic & translational research, while pharmaceutical & biotechnology companies commit a significant portion of R&D expenditure to preclinical in vivo models. Academic research institutions and specialized contract research organizations leverage this infrastructure and funding landscape to conduct target validation, toxicology, and efficacy studies, reinforcing North America's large share in the global mice model market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
• By Designation: C-level Executives - 55%, Directors- 20%, and Others- 25%
• By Region: North America -45%, Europe - 20%, the Asia Pacific -20%, Latin America -10%, the Middle East- 3%, and Africa-2%

Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), JSR Corporation (Japan), Biocytogen (China), TRANS GENIC INC. (Japan) Harbour BioMed (China), genOway (France), GemPharmatech (China), Cyagen (US), Ozgene Pty Ltd (Australia), Taconic Biosciences, Inc. (US), TransCure bioServices (France), Vivo Bio Tech Ltd (India), ingenious targeting laboratory (US), Janvier Labs (France), Champions Oncology, Inc (US), and Vitalstar Biotechnology Co., Ltd. (China) are some of the key companies offering mice model products & services.

Research Coverage:

This research report categorizes the mice model market by model type & service [model types (inbred mice, genetically engineered mice, hybrid/congenic mice, and outbred mice, breeding services, cryopreservation services, rederivation services, quarantine services, and other services)], by application (drug discovery & development, research applications, and personalized medicine), by technology (CRISPR/Cas9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies), by therapeutic area (oncology, neurology, immunology, metabolic diseases, cardiovascular diseases, and other therapeutic areas), by product end user (pharmaceutical & biotechnology companies, academic & research Institutes, and CROs & CDMOs), by services end user (pharmaceutical & biotechnology companies, government & biomedical research institutes, and CDMOs), and by region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa).

The report's scope covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the mice model market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the mice model market. This report covers the competitive analysis of upcoming startups in the mice model market ecosystem.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the mice model market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights on the following :

• Analysis of key drivers (high adoption of mice models in preclinical studies, the increasing demand for mouse clinical trials, the rising demand for personalized medicine in oncology, technological advancements in genetic engineering), restrains (the introduction of 3D printed models, ethical concerns, and regulatory restrictions), opportunities (Utilization of CRISPR in biomedical research, and the rising demand for disease-specific models), and challenges (development of alternative animal testing methods and genetic & phenotypic variability).
• Product approvals: Detailed insights into newly approved products of the mice models market.
• Market development: Comprehensive information about lucrative markets - the report analyses the mice model market across varied regions.
• Market diversification: Exhaustive information about new products, recent developments, and investments in the mice model market.
• Pipeline analysis: Comprehensive information about products under clinical trials.
• Competitive assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), JSR Corporation (Japan), and Biocytogen (China).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 INCLUSIONS & EXCLUSIONS
  • 1.3.2 MARKETS & REGIONS COVERED
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 BOTTOM-UP APPROACH
  • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
• 2.3 TOP-DOWN APPROACH
• 2.4 GROWTH FORECAST
• 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.6 RESEARCH ASSUMPTIONS
• 2.7 LIMITATIONS
• 2.8 MARKET FORECAST
• 2.9 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 MICE MODEL MARKET OVERVIEW
• 4.2 NORTH AMERICA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE (2024)
• 4.3 MICE MODEL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 MICE MODEL MARKET, BY MODEL TYPE (END USER), 2025 VS. 2030
• 4.5 MICE MODEL MARKET SHARE, BY SERVICES (END USER)

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 High adoption of mice models in preclinical studies
    • 5.2.1.2 Increasing demand for Mouse Clinical Trials (MCTs)
    • 5.2.1.3 Growing preference for personalized medicine in oncology
    • 5.2.1.4 Advancements in genetic engineering
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Introduction of 3D printed models
    • 5.2.2.2 Ethical concerns and regulatory restrictions
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Utilization of CRISPR in biomedical research
    • 5.2.3.2 Rising demand for disease-specific models
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Development of alternative animal testing methods
    • 5.2.4.2 Genetic & phenotypic variability
• 5.3 MICE MODEL MARKET LANDSCAPE
  • 5.3.1 HISTORY OF MICE MODELS
  • 5.3.2 MICE MODEL GENERATION PROCESS
  • 5.3.3 TECHNIQUES FOR MICE MODEL DEVELOPMENT
  • 5.3.4 TECHNOLOGICAL ADVANCEMENTS
  • 5.3.5 CONSIDERATIONS FOR MICE MODEL DEVELOPMENT
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024
  • 5.5.2 AVERAGE SELLING PRICE OF MODEL TYPES, BY REGION, 2024
• 5.6 ECOSYSTEM ANALYSIS
  • 5.6.1 MICE MODEL VENDORS
  • 5.6.2 MICE MODEL SERVICE VENDORS
  • 5.6.3 MICE MODEL END USERS
  • 5.6.4 REGULATORY ORGANIZATIONS
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 CRISPR/CAS9 gene editing
    • 5.7.1.2 Pronuclear Microinjection (PNI)
    • 5.7.1.3 Embryo cryopreservation & assisted reproduction
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 Multimodal preclinical imaging
    • 5.7.2.2 Automated behavioural phenotyping
    • 5.7.2.3 Integrated physiological monitoring
  • 5.7.3 ADJACENT TECHNOLOGIES
    • 5.7.3.1 Ex vivo CRISPR screening in cell culture
    • 5.7.3.2 High-content bioinformatics pipeline
    • 5.7.3.3 Mass spectroscopy-based tissue profiling
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.9 PATENT ANALYSIS
  • 5.9.1 METHODOLOGY
  • 5.9.2 PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
• 5.10 TRADE DATA ANALYSIS
  • 5.10.1 IMPORT DATA
  • 5.10.2 IMPORT DATA
• 5.11 KEY CONFERENCES & EVENTS
  • 5.11.1 KEY CONFERENCES & EVENTS (2025-2026)
• 5.12 TARIFF & REGULATORY LANDSCAPE
  • 5.12.1 TARIFF DATA (HS CODE 106.19.90)
  • 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.12.3 REGULATORY FRAMEWORK
    • 5.12.3.1 North America
    • 5.12.3.2 Europe
    • 5.12.3.3 China
    • 5.12.3.4 Japan
    • 5.12.3.5 India
    • 5.12.3.6 Australia
    • 5.12.3.7 Brazil
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 THREAT OF NEW ENTRANTS
  • 5.13.2 THREAT OF SUBSTITUTES
  • 5.13.3 BARGAINING POWER OF BUYERS
  • 5.13.4 BARGAINING POWER OF SUPPLIERS
  • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 ROLE OF STAKEHOLDERS IN BUYING PROCESS
  • 5.14.3 BUYING CRITERIA FOR MICE MODEL MARKET
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 IMPACT OF GENERATIVE AI ON MICE MODEL MARKET
  • 5.16.1 AI-USE CASES
  • 5.16.2 KEY COMPANIES IMPLEMENTING AI
• 5.17 CASE STUDIES
  • 5.17.1 CASE STUDY 1: AAV GENE EDITING IN CYAGEN LDLR MUTANT MICE AMELIORATES ATHEROSCLEROSIS
  • 5.17.2 CASE STUDY 2: METABOLIC EFFECTS OF SEMAGLUTIDE & TIRZEPATIDE IN DIET-INDUCED OBESE (DIO) MICEBAC
  • 5.17.3 CASE STUDY 3: TARGETING NATURAL KILLER CELL ACTIVITY WITH HUMANIZED NSG-IL15 MOUSE MODEL
• 5.18 TRUMP TARIFF IMPACT ON MICE MODEL MARKET
  • 5.18.1 KEY TARIFF RATES
  • 5.18.2 PRICE IMPACT ANALYSIS
  • 5.18.3 KEY IMPACT ON VARIOUS REGIONS
    • 5.18.3.1 US
    • 5.18.3.2 Europe
    • 5.18.3.3 Asia Pacific
    • 5.18.3.4 Rest of the World
  • 5.18.4 END-USE INDUSTRY IMPACT
    • 5.18.4.1 Pharmaceutical & biotechnology companies
    • 5.18.4.2 CROs & CDMOs
    • 5.18.4.3 Academic & research institutes

6 MICE MODEL MARKET, BY MODEL TYPE & SERVICE

• 6.1 INTRODUCTION
• 6.2 MODEL TYPE
  • 6.2.1 INBRED MICE
    • 6.2.1.1 High utilization across research applications to propel market
  • 6.2.2 GENETICALLY ENGINEERED MICE
    • 6.2.2.1 Ability to induce mutations for CVD & cancer research to drive market
  • 6.2.3 HYBRID/CONGENIC MICE
    • 6.2.3.1 Growing focus on biomedical research to boost demand
  • 6.2.4 OUTBRED MICE
    • 6.2.4.1 Genetic diversity benefits to support market growth
• 6.3 SERVICES
  • 6.3.1 BREEDING SERVICES
    • 6.3.1.1 Customization of models for specific research applications to boost demand
  • 6.3.2 CRYOPRESERVATION SERVICES
    • 6.3.2.1 Rising focus on preservation of novel mice models to propel market
  • 6.3.3 REDERIVATION SERVICES
    • 6.3.3.1 Stringent quality assurance standards to fuel market
  • 6.3.4 QUARANTINE SERVICES
    • 6.3.4.1 Rising demand for germ-free mice to support market growth
  • 6.3.5 OTHER SERVICES

7 MICE MODEL MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 CRISPR/CAS9
  • 7.2.1 ADVANTAGES SUCH AS SIMPLIFIED DESIGN AND COST EFFICIENCY TO PROPEL MARKET
• 7.3 MICROINJECTIONS
  • 7.3.1 LOW TOXICITY AND HIGH SUCCESS RATE TO DRIVE MARKET
• 7.4 EMBRYONIC STEM CELL INJECTIONS
  • 7.4.1 INCREASING DEMAND FOR TARGETED MICE MODELS IN IMMUNOLOGICAL RESEARCH TO FUEL MARKET
• 7.5 NUCLEAR TRANSFER TECHNIQUE
  • 7.5.1 POTENTIAL TO PRODUCE IDENTICAL MICE TO DRIVE MARKET
• 7.6 OTHER TECHNOLOGIES

8 MICE MODEL MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 DRUG DISCOVERY & DEVELOPMENT
  • 8.2.1 INCREASING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET
• 8.3 RESEARCH APPLICATIONS
  • 8.3.1 INCREASING FUNDING INVESTMENTS FOR CANCER RESEARCH TO DRIVE MARKET
• 8.4 PERSONALIZED MEDICINE
  • 8.4.1 INCREASING PREFERENCE FOR ONCOLOGY THERAPEUTICS TO SUPPORT MARKET GROWTH

9 MICE MODEL MARKET, BY THERAPEUTIC AREA

• 9.1 INTRODUCTION
• 9.2 ONCOLOGY
  • 9.2.1 GROWING FOCUS ON THERAPEUTIC DEVELOPMENT TO PROPEL MARKET
• 9.3 METABOLIC DISEASES
  • 9.3.1 INCREASING PREVALENCE OF ENDOCRINE DISORDERS TO DRIVE MARKET
• 9.4 IMMUNOLOGY
  • 9.4.1 RISING CLINICAL RESEARCH ACTIVITIES FOR IMMUNOLOGICAL DISORDERS TO FUEL MARKET
• 9.5 NEUROLOGY
  • 9.5.1 INCREASING INVESTMENTS IN R&D FOR CNS DISEASES TO BOOST DEMAND
• 9.6 CARDIOVASCULAR DISEASES
  • 9.6.1 GROWING FOCUS ON TARGETED TREATMENTS FOR CVD TO BOOST DEMAND
• 9.7 OTHER THERAPEUTIC AREAS

10 MICE MODEL TYPE MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.2.1 RISING EXPENDITURE ON R&D FOR DRUG DEVELOPMENT TO FUEL MARKET
• 10.3 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CROS & CDMOS)
  • 10.3.1 INCREASING OUTSOURCING OF DRUG DISCOVERY SERVICES TO DRIVE MARKET
• 10.4 ACADEMIC & RESEARCH INSTITUTES
  • 10.4.1 INCREASING FUNDING INITIATIVES FOR LIFE SCIENCES R&D TO SUPPORT MARKET GROWTH

11 MICE MODEL SERVICES MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.2.1 RISING OUTSOURCING OF PRECLINICAL SERVICES TO PROPEL MARKET
• 11.3 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS)
  • 11.3.1 DEVELOPMENT OF INTEGRATED MODELS AND GROWTH IN BIOLOGICS TO BOOST DEMAND
• 11.4 GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES
  • 11.4.1 FOCUS ON TRANSLATIONAL RESEARCH SERVICES TO SUPPORT MARKET GROWTH

12 MICE MODEL MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 Rising production of monoclonal antibodies to fuel market
  • 12.2.3 CANADA
    • 12.2.3.1 Growth in stem cell research activities to fuel market
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 Growth in biotechnology industry to drive market
  • 12.3.3 UK
    • 12.3.3.1 Increasing focus on cancer research to propel market
  • 12.3.4 FRANCE
    • 12.3.4.1 Rising investments in proteomics & genomics research to boost demand
  • 12.3.5 ITALY
    • 12.3.5.1 Growth in pharmaceutical & biotechnology industry to drive market
  • 12.3.6 SPAIN
    • 12.3.6.1 Extensive R&D pipeline to fuel uptake
  • 12.3.7 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 CHINA
    • 12.4.2.1 Favorable investments in life sciences research to drive market
  • 12.4.3 JAPAN
    • 12.4.3.1 Increasing focus on personalized diagnostics products to drive market
  • 12.4.4 INDIA
    • 12.4.4.1 Favorable initiatives for drug discovery & development to boost market
  • 12.4.5 AUSTRALIA
    • 12.4.5.1 High number of research institutes to favor market growth
  • 12.4.6 SOUTH KOREA
    • 12.4.6.1 Innovation in health & biotech sectors to support market uptake
  • 12.4.7 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Increasing investments in biopharmaceutical research to fuel uptake
  • 12.5.3 MEXICO
    • 12.5.3.1 Expanding healthcare ecosystem to support market growth
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST
  • 12.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST
  • 12.6.2 GCC COUNTRIES
    • 12.6.2.1 Kingdom of Saudi Arabia (KSA)
      • 12.6.2.1.1 Growing focus on advancement of healthcare sector to boost market
    • 12.6.2.2 United Arab Emirates
      • 12.6.2.2.1 Increasing R&D activities and growing demand for personalized medicine to propel market
    • 12.6.2.3 Other GCC Countries
  • 12.6.3 REST OF MIDDLE EAST
• 12.7 AFRICA
  • 12.7.1 RISING PRECISION MEDICINE INITIATIVES TO SUPPORT MARKET GROWTH
  • 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 OVERVIEW
• 13.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
  • 13.2.1 STRATEGIES ADOPTED BY KEY PLAYERS IN MICE MODEL MARKET, 2022-2025
• 13.3 REVENUE SHARE ANALYSIS, 2022-2024
• 13.4 MARKET SHARE ANALYSIS
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Region footprint
    • 13.5.5.3 Model type & service footprint
    • 13.5.5.4 Application footprint
    • 13.5.5.5 Technology footprint
    • 13.5.5.6 Therapeutic area footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 13.6.5.1 Detailed list of key startups/SME players
    • 13.6.5.2 Competitive benchmarking of key startups/SMEs
• 13.7 COMPANY VALUATION & FINANCIAL METRICS
  • 13.7.1 FINANCIAL METRICS
  • 13.7.2 COMPANY VALUATION
• 13.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 13.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS FOR MICE MODEL MARKET
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT/SERVICE LAUNCHES
  • 13.9.2 DEALS
  • 13.9.3 EXPANSIONS
  • 13.9.4 OTHER DEVELOPMENTS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 CHARLES RIVER LABORATORIES
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products/Services offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Deals
      • 14.1.1.3.2 Expansions
      • 14.1.1.3.3 Other developments
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses & competitive threats
  • 14.1.2 THE JACKSON LABORATORY
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products/Services offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Deals
      • 14.1.2.3.2 Expansions
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses & competitive threats
  • 14.1.3 INOTIV
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products/Services offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Deals
      • 14.1.3.3.2 Expansions
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses & competitive threats
  • 14.1.4 JSR CORPORATION
    • 14.1.4.1 Business overview
    • 14.1.4.2 Product/Services offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Deals
      • 14.1.4.3.2 Expansions
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Key strengths
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses & competitive threats
  • 14.1.5 BIOCYTOGEN
    • 14.1.5.1 Business overview
    • 14.1.5.2 Product/Services offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product/Service launches
      • 14.1.5.3.2 Deals
      • 14.1.5.3.3 Expansions
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Key strengths
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses & competitive threats
  • 14.1.6 SHANGHAI MODEL ORGANISMS CENTER, INC.
    • 14.1.6.1 Business overview
    • 14.1.6.2 Product/Services offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Deals
  • 14.1.7 TRANS GENIC INC.
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products/Services offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Deals
  • 14.1.8 HARBOUR BIOMED
    • 14.1.8.1 Business overview
    • 14.1.8.2 Product/Services offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Deals
      • 14.1.8.3.2 Other developments
  • 14.1.9 GENOWAY
    • 14.1.9.1 Business overview
    • 14.1.9.2 Product/Services offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Deals
  • 14.1.10 GEMPHARMATECH
    • 14.1.10.1 Business overview
    • 14.1.10.2 Product/Services offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Product/Service launches
      • 14.1.10.3.2 Deals
      • 14.1.10.3.3 Expansions
  • 14.1.11 CYAGEN
    • 14.1.11.1 Business overview
    • 14.1.11.2 Product/Services offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Deals
  • 14.1.12 OZGENE PTY LTD.
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products/Services offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Deals
  • 14.1.13 TACONIC BIOSCIENCES, INC.
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products/Services offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Product/Service launches
      • 14.1.13.3.2 Deals
      • 14.1.13.3.3 Expansions
  • 14.1.14 TRANSCURE BIOSERVICES
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products/Services offered
    • 14.1.14.3 Recent developments
      • 14.1.14.3.1 Deals
  • 14.1.15 VIVO BIO TECH LTD.
    • 14.1.15.1 Business overview
    • 14.1.15.2 Product/Services offered
  • 14.1.16 INGENIOUS TARGETING LABORATORY
    • 14.1.16.1 Business overview
    • 14.1.16.2 Product/Services offered
  • 14.1.17 JANVIER LABS
    • 14.1.17.1 Business overview
    • 14.1.17.2 Product/Services offered
    • 14.1.17.3 Recent developments
      • 14.1.17.3.1 Deals
  • 14.1.18 CHAMPIONS ONCOLOGY, INC.
    • 14.1.18.1 Business overview
    • 14.1.18.2 Products offered
    • 14.1.18.3 Recent developments
      • 14.1.18.3.1 Deals
  • 14.1.19 VITALSTAR BIOTECHNOLOGY CO., LTD.
    • 14.1.19.1 Business overview
    • 14.1.19.2 Products offered
• 14.2 OTHER PLAYERS
  • 14.2.1 ONCODESIGN SERVICES
  • 14.2.2 CLEA JAPAN, INC.
  • 14.2.3 APPLIED STEMCELL
  • 14.2.4 CREATIVE ANIMODEL
  • 14.2.5 JOINN LABORATORIES (CHINA) CO., LTD.
  • 14.2.6 CREATIVE BIOLABS
  • 14.2.7 CRESCENDO BIOLOGICS LIMITED
  • 14.2.8 ARAGEN LIFE SCIENCES LTD.
  • 14.2.9 POLYGENE
  • 14.2.10 PHARMTEST SERVICES
  • 14.2.11 MARSHALL BIORESOURCES

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS